RHAMM-R3 peptide vaccine (University of Ulm)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRHAMM-R3 peptide vaccine (University of Ulm)
Drug Alias NameRHAMM/CD168 R3 peptideRHAMM R3 peptide
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterUlm UniversityUniversite De Lausanne
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversite De LausanneUlm UniversityMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A